It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
T cells play a critical role in controlling viral infection; however, the mechanisms regulating their responses remain incompletely understood. Here, we investigated the role of topoisomerase IIA (Top2α, an enzyme that is essential in resolving entangled DNA strands during replication) in telomeric DNA damage and T cell dysfunction during viral infection. We demonstrated that T cells derived from patients with chronic viral (HBV, HCV, and HIV) infection had lower Top2α protein levels and enzymatic activity, along with an accumulation of the Top2α cleavage complex (Top2cc) in genomic DNA. In addition, T cells from virally infected subjects with lower Top2α levels were vulnerable to Top2α inhibitor-induced cell apoptosis, indicating an important role for Top2α in preventing DNA topological disruption and cell death. Using Top2α inhibitor (ICRF193 or Etoposide)-treated primary T cells as a model, we demonstrated that disrupting the DNA topology promoted DNA damage and T cell apoptosis via Top2cc accumulation that is associated with protein-DNA breaks (PDB) at genomic DNA. Disruption of the DNA topology was likely due to diminished expression of tyrosyl-DNA phosphodiesterase 2 (TDP2), which was inhibited in T cells in vitro by Top2α inhibitor and in vivo by chronic viral infection. These results suggest that immune-evasive viruses (HBV, HCV, and HIV) can disrupt T cell DNA topology as a mechanism of dysregulating host immunity and establishing chronic infection. Thus, restoring the DNA topologic machinery may serve as a novel strategy to protect T cells from unwanted DNA damage and to maintain immune competence.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 East Tennessee State University, Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673); Quillen College of Medicine, ETSU, Division of Infectious, Inflammatory and Immunologic Diseases, Department of Internal Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673)
2 East Tennessee State University, Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673)
3 University of Minnesota, Center for Drug Design, College of Pharmacy, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
4 East Tennessee State University, Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673); Quillen College of Medicine, ETSU, Division of Infectious, Inflammatory and Immunologic Diseases, Department of Internal Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673); Hepatitis (HCV/HBV/HIV) Program, James H. Quillen VA Medical Center, Department of Veterans Affairs, Johnson City, USA (GRID:grid.417066.2) (ISNI:0000 0004 0420 481X)